Novorapid Flexpen (Insulin Aspart)

Insulin aspart, the active ingredient in Novorapid Flexpen, is a rapid‑acting insulin analog presented as a solution for subcutaneous injection use. It controls blood glucose levels in people with diabetes mellitus. GNH USA supplies Novorapid Flexpen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Novorapid Flexpen is a rapid‑acting insulin analog that lowers post‑prandial glucose excursions in several diabetes‑related conditions.

- Type 1 diabetes mellitus: improves mealtime‑related glucose control. - Type 2 diabetes mellitus: provides mealtime insulin coverage when oral agents are insufficient. - Gestational diabetes mellitus: helps achieve target glucose levels after meals during pregnancy.

Adverse reactions to Novorapid Flexpen are reported across a spectrum of frequency.

Common Side Effects: - Hypoglycaemia: low blood glucose levels, especially if meals are missed or delayed. - Injection‑site reactions: redness, swelling, or itching at the injection site. - Lipodystrophy: localized changes in fat tissue with repeated injections. - Weight gain: modest increase associated with improved glycaemic control.

Serious or Rare Side Effects: - Severe hypoglycaemia with neuroglycopenic symptoms. - Allergic reactions: urticaria, angio‑edema, or anaphylaxis. - Hypersensitivity to any excipient in the pen device. - Persistent hyperglycaemia indicating possible insulin resistance.

When using Novorapid Flexpen, consider the following safety measures.

- Dose adjustment: modify insulin dose based on carbohydrate intake, activity level, and blood glucose trends. - Monitoring: perform regular self‑monitoring of blood glucose to avoid hypoglycaemia. - Concomitant medications: assess risk of hypoglycaemia when combined with sulfonylureas or meglitinides. - Pregnancy and lactation: use only if benefits outweigh potential risks and under medical supervision. - Renal or hepatic impairment: may require lower doses and closer monitoring. - Store at 2‑8°C: keep refrigerated, protect from light, do not freeze or shake.

Novorapid Flexpen may interact with other agents that influence blood glucose levels.

Major Interactions (Avoid): - Sulfonylureas or meglitinides: combined use can cause severe hypoglycaemia. - Beta‑blockers: may mask hypoglycaemia symptoms, complicating detection.

Moderate Interactions (Monitor Closely): - Corticosteroids: can increase insulin requirements. - Thiazide diuretics: may raise blood glucose. - Alcohol: can cause unpredictable glucose fluctuations. - Exercise: intense activity may necessitate dose reduction to prevent hypoglycaemia.